

**MECHANISMS UNDERLYING METABOLIC AND
CARDIOVASCULAR ADVERSE EFFECTS OF SOME ATYPICAL
ANTIPSYCHOTIC DRUGS IN EXPERIMENTAL ANIMALS**

A thesis submitted for partial fulfillment of M.D. degree in pharmacology

By

Mohamed Hamdy Bahr; M.B., B.Ch. (Ain Shams)
Assistant Lecturer in Pharmacology
Department of Pharmacology & Therapeutics
Faculty of Medicine, Ain Shams University

Supervision

Prof. Dr. Adel Desawy Bakry, Ph.D (Ain Shams)
Professor of pharmacology
Department of pharmacology & therapeutics
Faculty of medicine, Ain Shams University

Dr. Salwa Abdel-Khalek Nawishy, Ph.D. (London)
Assistant Professor of Clinical Psychopharmacology
Department of pharmacology & therapeutics
Faculty of medicine, Ain Shams University

Dr. Sawsan Aboul Fotouh El-Said, Ph.D. (Ain Shams)
Lecturer in pharmacology
Department of pharmacology & therapeutics
Faculty of medicine, Ain Shams University

**Ain Shams University
Cairo, Egypt**

2009

ACKNOWLEDGMENTS

I acknowledge *Prof. Dr. Adel Desawy Bakry*, Professor of Pharmacology, Department of Pharmacology & Therapeutics, Faculty of Medicine, Ain Shams University, for his wholehearted encouragement, valuable advice, and support throughout this work.

I am deeply indebted to *Dr. Salwa Abdel-Khalek Nawishy*, Assistant Professor of Clinical Psychopharmacology, Department of Pharmacology & Therapeutics, Faculty of Medicine, Ain Shams University, for her discrete guidance and support for this work, starting with choice of the topic, provision with expert advice and tips and supplementation with relevant drug info, as well as punctually reviewing and editing the whole manuscript.

My gratitude to *Dr. Sawsan Aboul Fotouh El-Said*, Lecturer of Pharmacology, Department of Pharmacology & Therapeutics, Faculty of Medicine, Ain Shams University, for her assistance and consistent follow up, starting from sketching out the hypothesis, invaluable revision and critique of the methodology and results management and presentation, as well as thorough revision of the material all through.

Special thanks to the professors *Prof. Dr. Ahmed Abdel-Salam*, Department of Pharmacology & Therapeutics, for supplying olanzapine and *Prof. Dr. Mahmoud Ismael Hassan*, Department of Biochemistry, for his assistance in performing chemical assays.

Thanks also for the morale and support of staff members and my colleagues.

TABLE OF CONTENTS

Title	Page
LIST OF FIGURES	vii
LIST OF TABLES	xi
LIST OF ABBREVIATIONS	xv
ABSTRACT	xvii
CHAPTER (1): INTRODUCTION	3
ANTIPSYCHOTIC DRUGS	3
History.....	3
Conventional Antipsychotic Drugs.....	3
Atypical Antipsychotic Drugs.....	4
Mechanism of Action of Atypical Antipsychotic Drugs.....	6
Advantages of Atypical Antipsychotic Drugs.....	8
Selected Atypical Antipsychotic Drugs.....	11
Olanzapine.....	11
Ziprasidone.....	14
Adverse Effects of Atypical Antipsychotics and Their Possible Mechanisms.....	17
Weight Gain.....	20
Receptor Antagonism.....	21
Insulin Resistance, Diabetes Mellitus.....	23
Dyslipidemias.....	28
Leptin.....	29
Acute Pancreatitis.....	30
Nonmetabolic Adverse Effects.....	32
Animal Models to Study Antipsychotic-Induced Weight Gain.....	34

CHAPTER (2): AIM OF THE WORK.....	39
CHAPTER (3): MATERIALS AND METHODS.....	43
CHAPTER (4): RESULTS.....	63
I. Effect of Chronic Antipsychotic and H ₁ /5-HT _{2C} Antagonist Treatment on Food Intake and Body Weight Gain.....	65
A. Food Intake.....	65
B. Body Weight Gain.....	69
II. Effect of Chronic Antipsychotic and H ₁ /5-HT _{2C} Antagonist Treatment on Body Composition (Brown Adipose Tissue and Adiposity Index).....	73
III. Effect of Chronic Antipsychotic and H ₁ /5-HT _{2C} Antagonist Treatment on Serum Glucose, Insulin, and HOMA-IR.....	77
IV. Effect of Chronic Antipsychotic and H ₁ /5-HT _{2C} Antagonist Treatment on Serum Leptin.....	83
V. Effect of Chronic Antipsychotic and H ₁ /5-HT _{2C} Antagonist Treatment on Serum Total Lipid Profile.....	85
VI. Pearson Correlation Analysis.....	93
VII. An Overview.....	96
CHAPTER (5): DISCUSSION.....	101
CHAPTER (6): SUMMARY.....	139
CHAPTER (7): REFERENCES.....	145
APPENDIX.....	175
ARABIC SUMMARY	

LIST OF FIGURES

Figure (1) *Cumulative daily food intake* chronically (gm), Mean in female rats for 21 days treated with ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 67

Figure (2) A bar-chart comparing the mean±standard error (SE) of *total food intake* chronically (gm) in female rats for 21 days treated with ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined..... Page 68

Figure (3) *Cumulative body weight gain* (represented as percentage of the initial body weight) in female rats for 21 days treated with ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 71

Figure (4) A bar-chart comparing the mean±standard error (SE) of *percentage of total body weight gain* in female rats chronically after 21 days treated with ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 72

Figure (5) A bar-chart comparing the mean±standard error (SE) of *brown adipose tissue* (% of body weight) in rats following chronic

administration of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 74

Figure (6) A bar-chart comparing the mean±standard error (SE) of *adiposity index* in rats following chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 76

Figure (7) A bar-chart comparing the mean±standard error (SE) of *serum glucose* (mM) in rats following chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 78

Figure (8) A bar-chart comparing the mean±standard error (SE) of *serum insulin* (mU) in rats following chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 80

Figure (9) A bar-chart comparing the mean±standard error (SE) of *HOMA-IR* in rats following chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 82

Figure (10) A bar-chart comparing the mean±standard error (SE) of *serum leptin* (ng/ml) in rats following chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 84

Figure (11) A bar-chart comparing the mean±standard error (SE) of *serum triglycerides* (mg/dl) in rats following chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 86

Figure (12) A bar-chart comparing the mean±standard error (SE) of *total cholesterol* (mg/dl) in rats following chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 88

Figure (13) A bar-chart comparing the mean±standard error (SE) of *HDL-C* (mg/dl) in rats following chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 90

Figure (14) A bar-chart comparing the mean±standard error (SE) of *LDL-C* (mg/dl) in rats following chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA)

(2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 92

Figure (15) A bubble-chart showing Pearson correlation coefficient (r) for results of food intake, body weight gain, insulin, glucose, HOMA-IR, leptin, adiposity index, brown adipose tissue, triglycerides, cholesterol, HDL, and LDL measured in the study.....Page 95

Figure (16) Interplay of possible mechanisms contributing to olanzapine-induced weight gain and related metabolic dysregulation. Collaboration of the present study findings with current relevant literature.....Page 175

LIST OF TABLES

- Table (1): Receptor Systems Affected by AAPDs..... Page 7
- Table (2): The Main Characteristics of AAPDs..... Page 7
- Table (3): The Five major features of the metabolic syndrome...Page 18
- Table (4): Nutritional composition (per 100 gm) of the components of rat diet employed in the present study.....Page 46
- Table (5) *Cumulative daily food intake* chronically (gm) in female rats for 21 days treated with ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 66
- Table (6) *Cumulative body weight gain* (represented as percentage of the initial body weight) in female rats for 21 days treated with ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined.....Page 70
- Table (7) Effect of chronic (21 days) administration of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined, on *brown adipose tissue* (% of body weight) in female rats.....Page 73
- Table (8) Effect of chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10

mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined, on *adiposity index* in female rats...Page 75

Table (9) Effect of chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined, on *serum glucose* (mM) in female rats.....Page 77

Table (10) Effect of chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined, on *serum insulin* (mU) in female rats.....Page 79

Table (11) Effect of chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined, on *HOMA-IR* in female rats.....Page 81

Table (12) Effect of chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined, on *serum leptin* (ng/ml) in female rats.....Page 83

Table (13) Effect of chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.),

either single or combined, on <i>serum triglycerides</i> (mg/dl) in female rats.....	Page 85
Table (14) Effect of chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined, on <i>total cholesterol</i> (mg/dl) in female rats.....	Page 87
Table (15) Effect of chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined, on <i>HDL-C</i> (mg/dl) in female rats.....	Page 89
Table (16) Effect of chronic administration after 21 days of ziprasidone (ZIP) (10 mg/kg/day p.o.), olanzapine (OLA) (2 mg/kg/day p.o.), SB 242084 (0.3 mg/kg/day i.p.), chlorpheniramine (CPA) (10 mg/kg/day i.p.), and cyproheptadine (CYP) (10 mg/kg/day i.p.), either single or combined, on <i>LDL-C</i> (mg/dl) in female rats.....	Page 91
Table (17): Correlation matrix showing Pearson correlation coefficient (r) (displayed as %) for results of food intake, body weight gain, insulin, glucose, HOMA-IR, leptin, adiposity index, brown adipose tissue, triglycerides, cholesterol, HDL, and LDL measured in the study.....	Page 94
Table (18): An overview of the findings of the present study.....	Page 97
Table (19): Main studies modeling APD-induced weight gain...	Page 175

LIST OF ABBREVIATIONS

5-HT	5-hydroxytryptamine; serotonin
5-HIAA	5-hydroxyindole acetic acid
AAPDs	atypical antipsychotic drugs
APDs	antipsychotic drugs
ACh	acetylcholine
AI	adiposity index
AgRP	agouti-related protein
AMP	adenosine monophosphate
ANOVA	analysis of variance
ARC	arcuate nucleus of the hypothalamus
BAT	brown adipose tissue
BDNF	brain-derived neurotropic factor
BMI	body mass index
BPRS	Brief Psychiatric Rating Scale
BWG	body weight gain
CART	cocaine-and-amphetamine-regulated transcript
CATIE	Clinical Antipsychotic Trials of Intervention Effectiveness
CGI	Clinical Global Impression
CHD	coronary heart disease
Chol	cholesterol
CMS	chronic mild stress
CNS	central nervous system
CPA	chlorpheniramine
CVD	cardiovascular diseases
CYP	cyproheptadine
D	dopamine
DEXA	dual energy X-ray absorptiometry
DI	disposition index
DiSCO	Diabetes in Schizophrenia in Central-south Ontario
DKA	diabetic ketoacidosis
DM	diabetes mellitus
DMSO	dimethyl sulfoxide
ELISA	enzyme-linked immunosorbant assay
EPS	extrapyramidal syndrome; extrapyramidal side effects
ER	extended release
FDA	Food and Drug Administration
FI	food intake
Glc	glucose
H	histamine
HDL	high density lipoproteins